Royal Bank Of Canada Analysts Give Allergan PLC. (AGN) a $284.00 Price Target
Allergan PLC. (NYSE:AGN) has been assigned a $284.00 price target by research analysts at Royal Bank Of Canada in a note issued to investors on Sunday. The firm presently has a “buy” rating on the stock. Royal Bank Of Canada’s target price indicates a potential upside of 14.73% from the stock’s current price.
Several other equities analysts have also recently commented on the stock. Piper Jaffray Companies reissued a “hold” rating and set a $231.00 target price on shares of Allergan PLC. in a research report on Friday. Zacks Investment Research raised shares of Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 target price on the stock in a research report on Tuesday, July 11th. BidaskClub raised shares of Allergan PLC. from a “hold” rating to a “buy” rating in a research report on Saturday, June 24th. Vetr raised shares of Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 target price on the stock in a research report on Monday, June 26th. Finally, Cantor Fitzgerald assumed coverage on shares of Allergan PLC. in a research report on Friday, June 16th. They set a “neutral” rating and a $231.00 target price on the stock. Seven investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $273.15.
Shares of Allergan PLC. (NYSE:AGN) traded up 0.68% during trading on Friday, reaching $247.53. The company’s stock had a trading volume of 1,438,443 shares. The stock’s 50 day moving average price is $231.35 and its 200-day moving average price is $230.10. The firm has a market cap of $83.14 billion, a PE ratio of 7.71 and a beta of 1.16. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $261.27.
Allergan PLC. (NYSE:AGN) last posted its earnings results on Tuesday, May 9th. The company reported $3.35 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.32 by $0.03. Allergan PLC. had a net margin of 82.42% and a return on equity of 7.29%. The firm had revenue of $3.57 billion for the quarter, compared to analysts’ expectations of $3.53 billion. During the same quarter last year, the firm earned $3.04 EPS. The company’s quarterly revenue was up 5.1% compared to the same quarter last year. Equities analysts predict that Allergan PLC. will post $16.09 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Royal Bank Of Canada Analysts Give Allergan PLC. (AGN) a $284.00 Price Target” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/07/16/royal-bank-of-canada-reiterates-buy-rating-for-allergan-plc-nyseagn.html.
In other news, Director Nesli Basgoz sold 1,889 shares of the business’s stock in a transaction on Thursday, May 18th. The shares were sold at an average price of $220.45, for a total transaction of $416,430.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.36% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Baupost Group LLC MA increased its stake in Allergan PLC. by 71.5% in the fourth quarter. Baupost Group LLC MA now owns 3,432,603 shares of the company’s stock worth $720,881,000 after buying an additional 1,430,625 shares in the last quarter. Trust Co. of Vermont increased its stake in Allergan PLC. by 62.8% in the first quarter. Trust Co. of Vermont now owns 2,875 shares of the company’s stock worth $687,000 after buying an additional 1,109 shares in the last quarter. BKD Wealth Advisors LLC bought a new stake in Allergan PLC. during the first quarter worth about $219,000. Fulton Bank N.A. increased its stake in Allergan PLC. by 12.8% in the first quarter. Fulton Bank N.A. now owns 5,602 shares of the company’s stock worth $1,338,000 after buying an additional 637 shares in the last quarter. Finally, Rehmann Capital Advisory Group increased its stake in Allergan PLC. by 15.4% in the first quarter. Rehmann Capital Advisory Group now owns 1,780 shares of the company’s stock worth $425,000 after buying an additional 237 shares in the last quarter. Hedge funds and other institutional investors own 84.53% of the company’s stock.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.